Phase I Clinical Trial of Locoregional Administration of the Oncolytic Adenovirus ONYX-015 in Combination with Mitomycin-C, Doxo
Despite many advances in cancer therapy, metastatic disease continues to be incurable in the majority of cancer patients. There ia an need for more efficient and less toxic treatments is this setting. Oncolytic virotherapy represents a novel promising direction in the treatment of cancer. Based on preclinical and clinical data, combination with standard chemotherapy has the potential to further increase the antitumor activity of oncolytic virotherapy in a synergistic manner. We present the design of a phase I clinical trial combining intratumoral injections of the oncolytic adenovirus ONYX-015 with systemic chemotherapy in patients with advanced sarcomas.
- Genetic Alterations in Esophageal Cancer
- Non-RI Protocols for L-myc Allelotyping and Deletion Mapping of Chromosome 1p in Primary Lung Cancers
- Cytogenetic Studies in Hematologic Malignancies: An Overview
- Preparation of DNA-Protein Complexes Suitable for Spectroscopic Analysis
- LHRH-Targeted Nanoparticles for Cancer Therapeutics
- Applications of Tissue Microdissection in Molecular Pathology: Principles and Guidelines
- Origin and Pathogenesis of B Cell Lymphomas
- Cancer Occurrence
- Quantitation of FISH Signals in Archival Tumors
- 美开发出成体细胞转化为干细胞新方法